Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Alterations in the phosphatase and tensin homolog (PTEN) are correlated with tumor progression. Downregulation of PTEN is related to drug resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the prognostic significance of PTEN in patients with NSCLC and its correlation with EGFR. Methods: Two hundred eighty eight surgically resected NSCLC samples, including 168 adenocarcinomas (ADCs), 99 squamous cell carcinomas (SCCs) and 21 other NSCLCs were analyzed for the PTEN. The results were correlated with other clinicopathological variables including EGFR amplification and mutation. Results: Loss of PTEN was detected in 42.4% of NSCLCs, specifically 28.6% of ADCs, 66.7% of SCCs, and 38.1% of others. Loss of PTEN was significantly associated with SCC, smoking, male gender, and higher stage. In a multivariate analysis, loss of PTEN was significantly associated with short progression-free survival (p=0.037). No association between PTEN and EGFR was observed. Conclusions: These results suggest that loss of PTEN results in shorter progression-free survival in patients with NSCLC, and loss of PTEN is more associated with SCC, smoking, male gender, and higher T stage by the 7th tumor, node and metastasis staging system but not EGFR status.
Abstract
Background: Alterations in the phosphatase and tensin homolog (PTEN) are correlated with tumor progression. Downregulation of PTEN is related to drug resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the prognostic significance of PTEN in patients with NSCLC and its correlation with EGFR. Methods: Two hundred eighty eight surgically resected NSCLC samples, including 168 adenocarcinomas (ADCs), 99 squamous cell carcinomas (SCCs) and 21 other NSCLCs were analyzed for the PTEN. The results were correlated with other clinicopathological variables including EGFR amplification and mutation. Results: Loss of PTEN was detected in 42.4% of NSCLCs, specifically 28.6% of ADCs, 66.7% of SCCs, and 38.1% of others. Loss of PTEN was significantly associated with SCC, smoking, male gender, and higher stage. In a multivariate analysis, loss of PTEN was significantly associated with short progression-free survival (p=0.037). No association between PTEN and EGFR was observed. Conclusions: These results suggest that loss of PTEN results in shorter progression-free survival in patients with NSCLC, and loss of PTEN is more associated with SCC, smoking, male gender, and higher T stage by the 7th tumor, node and metastasis staging system but not EGFR status.
참고문헌 (24)
- Jemal A, "Cancer statistics, 2007", CA Cancer J Clin, 57, pp.43~66 (2007)
- Crystal AS, "New targets in advanced NSCLC: EML4-ALK", Clin Adv Hematol Oncol, 9, pp.207~214 (2011)
- Uramoto H, "Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma", Lung Cancer, 73, pp.361~365 (2011)
- Li J, "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer", Science, 275, pp.1943~1947 (1997)
- Stambolic V, "Negative regulation of PKB", Akt-dependent cell survival by the tumor suppressor PTEN, 1998, pp.95, 29~39
- Marsh DJ, "Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation", Hum Mol Genet, 7, pp.507~515 (1998)
- Wang SI, "Somatic mutations of PTEN in glioblastoma multiforme", Cancer Res, 57, pp.4183~4186 (1997)
- Kang YH, "Promoter methylation and silencing of PTEN in gastric carcinoma", Lab Invest, 82, pp.285~291 (2002)
- Marsit CJ, "PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration", Hum Pathol, 36, pp.768~776 (2005)
- Uramoto H, "Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer", Br J Cancer, 96, pp.857~863 (2007)
- Uramoto H, "Resistance to gefitinib", Int J Clin Oncol, 11, pp.487~491 (2006)
- Yamamoto C, "Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations", Cancer Res, 70, pp.8715~8725 (2010)
- Yoo SB, "Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study", Lung Cancer, 67, pp.301~305 (2010)
- Travis W, "World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart" (2004), IARC Press
- Postmus PE, "The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer", J Thorac Oncol, 2, pp.686~693 (2007)
- Chang YL, "Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers", Clin Cancer Res, 13, pp.52~58 (2007)
- Gallegos Ruiz MI, "Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization", Histopathology, 51, pp.631~637 (2007)
- Tang JM, "Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis", Lung Cancer, 51, pp.181~191 (2006)
- Jiang Z, "Expression and significance of PTEN and nm23-H1 in the metastasis of non-small cell lung cancer", Zhongguo Fei Ai Za Zhi, 11, pp.793~797 (2008)
- Lim WT, "PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer", Oncol Rep, 17, pp.853~857 (2007)
- Zhang H, "Expression of PTEN, p53 and P-glycoprotein in non-small cell lung cancer and their predictive values", Zhongguo Fei Ai Za Zhi, 12, pp.1213~1216 (2009)
- Liao DW, "Expression and significance of PTEN", PI3K signal transduction-related proteins in non-small cell lung cancer, 2006, pp.25, 1238~1242
- Lee HJ, "CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification", J Thorac Oncol, 5, pp.649~657 (2010)
- Yamasaki F, "Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1", PTEN and up-regulation of phosphorylated Akt, 2007, pp.67, 5779~5788